This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Godwin JL , Hoffman-Censits J , Plimack E
Recent developments in the treatment of advanced bladder cancer
Urol Oncol. 2018 Mar;36(3) :109-114
PMID: 29395952 URL: https://www.ncbi.nlm.nih.gov/pubmed/29395952
AbstractUrothelial carcinoma of the bladder is a common malignancy which has historically been difficult to treat in its advanced stages. Clinically effective treatment options for locally advanced/inoperable or metastatic urothelial carcinoma (mUC) consisted of cisplatin-based chemotherapy regimens, with few other impactful therapeutic options. The past 2 years have seen a remarkable shift in the therapeutic landscape of mUC, with 5 novel immunotherapy agents receiving FDA approval for mUC, including first-line and second-line postplatinum settings. There are now many important clinical trials ongoing seeking to answer how best to use chemotherapy, immunotherapy, and targeted therapy agents in patients with mUC. Here we review the current standard of care for patients with mUC based on published data from the past 2 years, and look forward toward future research directions.
Notes1873-2496 Godwin, James Luke Hoffman-Censits, Jean Plimack, Elizabeth Journal Article Review United States Urol Oncol. 2018 Jan 26. pii: S1078-1439(17)30647-6. doi: 10.1016/j.urolonc.2017.12.018.